Navigation Links
Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Date:4/6/2009

e new Clinical Supplies module as well as other innovative functional changes to the system that will lead to process efficiencies and cost savings," said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

About Clinical Force
Clinical Force delivers a fully functional Clinical Trials Management System (CTMS) to Clinical Research Organizations and Sponsors. Clinical Force is the first company to deliver the CTMS in the Software as a Service (SaaS) model enabling quick installation and a cost effective solution. Organizations in North America, South America, Africa and Europe are successfully using the CTMS to improve internal efficiencies and real time visibility of all studies from an easy to use web based solution. Clinical Force is a privately held company with strong life science pedigree, the company has offices in the US and Europe. www.clinicalforce.com

About Gemin X Pharmaceuticals
Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, inducing cancer cell self-digestion, or autophagy, and the inhibition of metabolism in cancerous cells. Gemin X currently has several clinical development programs underway, including Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, and preclinical studies for its Telomere Capping and SMAC Mimetic programs. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis.

For more information, please visit

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
2. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
5. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
6. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
7. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
8. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
9. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... Dental decay is the number one ... For Dr. Crisafulli of Crisafulli Dental those statistics are no ... the world and implemented a cavity prevention program developed by ... by up to 74% . The system is ... finally found a solution to dental decay that works,” says ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 For ... offers Waterless Bead Baths using metallic beads ... less electricity, and do not require germicides. Yet, the ... and, because the bath is always ready unlike a ... beads create a dry bath, which eliminates the contamination ...
(Date:6/19/2013)... 2013 Research and ... addition of the "Global Biometric Systems ... to their offering.      (Logo: ... protection and old security practises such as ... the growth of biometric technologies in last ...
(Date:6/19/2013)... 19, 2013  Continuing its long history of proven ... Beckman Coulter , Inc. announces the U.S. Food and ... AccuTnI+3 troponin I assay for use on its Access ... on Beckman Coulter,s troponin I test for ... the proven performance to continue providing dependability to laboratories ...
Breaking Biology Technology:Crisafulli Dental Launches Ground Breaking Cavity Prevention Program That Can Lower Decay Rates by 74% 2Cole-Parmer Introduces Eco-Friendly Waterless Bead Baths 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3
... 27 The American Stock Exchange(R),(Amex(R)) today lists ... ticker,symbol CUR. Neuralstem, Inc. is a biotechnology ... cell technology in the field of,regenerative medicine. ... Exchange," said,John McGonegal, Senior Vice President of Amex,s ...
... 27 NovaQuest has,made a strategic investment ... specializing in respiratory,disorders. The investment was part ... million) in the Montreal-based company. Last ... partnering group,of Quintiles Transnational, helps TOPIGEN accelerate ...
... 27 DHA omega-3 innovator,Martek Biosciences announced today that ... featured in new Ricos(R) Cheese Sauce.,Sold to schools throughout ... of,DHA per serving in the standard foodservice packaging of ... 3.5 oz. single serve cup which contains 50 mg,of ...
Cached Biology Technology:NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 3
(Date:6/18/2013)... environmental engineer has been awarded a $394,300 grant ... water quality and flow in the new facilities ... Kruzic, UT Arlington associate professor of civil engineering, ... add monochloramine to the water in an effort ... stations and pipelines. Adding monochloramine is widely practiced ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... press release isn't very clear, especially when it comes to ... at the end if you want to understand what the ... Kingdom, February 16, 2005 -- The European Vaccine Effort against ... novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention ...
... a new blow to the dominant evolutionary paradigm, Luiz ... Harvard University the University of Florida and the University ... may differ more from one another than from fish ... coral reef organisms may spur the development of a ...
... of the mouth and throat, surgery is a ... and swallowing dysfunction and external scarring. Researchers from ... of Otorhinolaryngology/Head and Neck Surgery, have completed two ... ?that demonstrate the effective use of the daVinci ...
Cached Biology News:'EuroVacc 02' HIV Vaccine Trial Begins 2'EuroVacc 02' HIV Vaccine Trial Begins 3An (ecological) origin of species for tropical reef fish 2Penn Researchers Use Robotic Surgery 2Penn Researchers Use Robotic Surgery 3
Request Info...
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: